December 06, 2025 05:11 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
In front of Putin, PM Modi makes bold statement on Russia-Ukraine war: ‘India is not neutral, we side with peace!’ | Rupee weakens following RBI repo rate cut | RBI slashes repo rate by 25 basis points — big relief coming for borrowers! | 'Mamata fooled Muslims': Humayun Kabir explodes after TMC suspends him over 'Babri Masjid-style mosque' demand; announces new party | Mosque in the middle of Kolkata airport? Centre confirms flight risks, BJP fires at Mamata | Sam Altman is betting big on India! OpenAI in advanced talks with Tata to build AI infrastructure | Government removes mandatory pre-installation of Sanchar Saathi App. Know all details | Calcutta HC overturns controversial Bengal job annulment — 32,000 teachers rejoice! | Bengal SIR shock: 1 lakh ‘deceased voters’ found in Kolkata North! | Massive twist in Bengal voter list: ‘Perfect’ 2,280 booths shrink to just 480 after probe!
India COVID19
UNI

India registers 5,379 new COVID-19 cases in past 24 hours, active caseload stands at 50,594

| @indiablooms | Sep 07, 2022, at 03:27 pm

New Delhi: India registered 5,379 new COVID-19 cases in the past 24 hours as the active caseload currently stands at 50,594, as per data released by the Ministry of Health on Wednesday.

The daily positivity rate touched 1.67 percent.

Active cases stand at 0.11 percent.

Recovery Rate currently at 98.7 percent.

7,094 people recovered from the viral disease in the past 24 hours.

Meanwhile, Bharat Biotech International Limited (BBIL) Tuesday announced that iNCOVACC (BBV154), its intra-nasal vaccine against Covid-19, has received approval under restricted use in an emergency situation for ages 18 and above in India.

iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein, the Hyderabad-based vaccine maker said in a release here.

This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results.

iNCOVACC has been specifically formulated to allow intranasal delivery through nasal drops.

The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries.

iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.